|
Mechanism30S subunit inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date05 Dec 1967 |
100 Clinical Results associated with Chartwell Pharma NDA B2 Holdings, LLC.
0 Patents (Medical) associated with Chartwell Pharma NDA B2 Holdings, LLC.
100 Deals associated with Chartwell Pharma NDA B2 Holdings, LLC.
100 Translational Medicine associated with Chartwell Pharma NDA B2 Holdings, LLC.